+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
HIV or AIDS Diagnostics Market - Global Forecast 2026-2032- Product Image
HIV or AIDS Diagnostics Market - Global Forecast 2026-2032- Product Image
Sale

HIV or AIDS Diagnostics Market - Global Forecast 2026-2032

  • Report

  • 196 Pages
  • August 2026
  • Region: Global
  • 360iResearch™
  • ID: 4904396
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The HIV or AIDS Diagnostics Market is projected to reach USD 2.76 Billion in 2026. It is expected to continue growing at a CAGR of 6.56%, reaching USD 4.06 Billion by 2032.

HIV and AIDS diagnostics remain central to global prevention, treatment initiation, viral suppression monitoring, and public health surveillance. UNAIDS reported approximately 39.9 million people living with HIV in 2023, with 1.3 million new HIV infections and 630,000 AIDS-related deaths, reinforcing the continued need for earlier, more accessible, and more accurate HIV testing.

The HIV diagnostics landscape is shaped by laboratory-based fourth-generation antigen-antibody assays, nucleic acid testing, point-of-care rapid tests, HIV self-testing, CD4 monitoring, viral load testing, and confirmatory algorithms. Demand is supported by health systems pursuing the UNAIDS 95-95-95 targets, expanding community-based screening, and integrating diagnostics into sexual health, maternal health, tuberculosis, and harm-reduction programs.

Transformative Shifts in the HIV Diagnostics Landscape

The HIV diagnostics landscape is shifting from centralized, episodic testing toward decentralized, digitally connected, and patient-centered models. WHO-backed strategies emphasize differentiated HIV testing services, including provider-initiated testing, community testing, partner services, and HIV self-testing to reach populations underserved by conventional clinics.

Technology adoption is also changing procurement and implementation priorities. Laboratories continue to rely on high-throughput immunoassay platforms and molecular systems, while public health programs are expanding rapid diagnostic tests, dried blood spot collection, and near-patient viral load solutions. Regulatory rigor, supply chain resilience, quality assurance, and assay performance across HIV-1 groups and HIV-2 remain critical competitive factors.

Cumulative Impact of Artificial Intelligence on HIV Diagnostics

Artificial intelligence is beginning to influence HIV and AIDS diagnostics through risk stratification, laboratory workflow automation, quality control, digital test reading, outbreak signal detection, epidemiological analytics, and linkage-to-care optimization. AI-enabled tools can help health systems identify testing gaps, prioritize outreach, improve appointment follow-up, and reduce delays between diagnosis and antiretroviral therapy initiation.

The impact remains cumulative rather than fully disruptive because HIV diagnosis depends on validated assays, regulated testing algorithms, and confirmatory standards. Industry leaders should treat AI as a decision-support layer that improves efficiency, data quality, and public health targeting, while maintaining clinical validation, explainability, privacy safeguards, cybersecurity controls, and compliance with FDA, WHO, IVDR, and local regulatory expectations.

Key Regional Insights Across Global HIV Diagnostics

Asia-Pacific is a high-priority region due to large populations, expanding diagnostic infrastructure, and national HIV programs in China, India, Japan, Australia, South Korea, and ASEAN markets. Regional demand is supported by hospital-based immunoassay testing, molecular platforms, antenatal screening, blood safety programs, and community outreach, while rural access, stigma, and uneven linkage to care continue to influence testing uptake.

North America remains a mature HIV diagnostics region characterized by fourth-generation laboratory testing, nucleic acid testing, PrEP-linked screening, strong public health surveillance, and guideline-led confirmatory testing. Latin America, led by Brazil and Mexico, is expanding access through public-sector procurement, community testing, and integrated HIV care pathways. Europe benefits from established laboratory networks, national screening guidelines, and EU regulatory harmonization, although late diagnosis remains a concern in parts of the region. The Middle East is shaped by centralized testing models, migrant screening, and privacy-sensitive care pathways, while Africa represents the highest public health need, with UNAIDS identifying sub-Saharan Africa as the region carrying the largest share of the global HIV burden and requiring sustained access to rapid testing, viral load monitoring, and early infant diagnosis.

Key Group Insights for HIV & AIDS Diagnostics

ASEAN markets are advancing HIV testing through national programs, donor-supported procurement, self-testing pilots, antenatal screening, and outreach to key populations, with cross-border mobility making surveillance and linkage to care important. The GCC is defined by high-income health systems, centralized laboratories, migrant health screening, premarital and occupational testing policies in some settings, and strong demand for confidential, regulated testing pathways.

The European Union is influenced by the In Vitro Diagnostic Regulation, which raises expectations for clinical evidence, performance evaluation, traceability, and post-market surveillance. BRICS countries combine large testing volumes with diverse reimbursement and procurement models, making affordability, local manufacturing capacity, scalable molecular testing, and public-sector access essential. G7 markets drive innovation in high-throughput assays, digital reporting, laboratory automation, and AI-enabled analytics, while NATO countries emphasize resilient diagnostics, military readiness, emergency preparedness, and biosurveillance interoperability.

Key Country Insights in HIV Diagnostics

The United States has a highly developed HIV diagnostics ecosystem supported by CDC testing recommendations, fourth-generation assays, confirmatory differentiation tests, HIV RNA testing for acute infection, PrEP-related screening, and strong surveillance infrastructure. Canada emphasizes public health screening, Indigenous health equity, harm-reduction-linked testing, and access across geographically dispersed populations, while Mexico and Brazil rely on public-sector testing networks, community outreach, antenatal programs, and HIV service integration to improve earlier diagnosis.

In Europe, the United Kingdom, Germany, France, Italy, and Spain maintain strong laboratory capacity, guideline-driven testing, blood safety systems, and expanding community-based approaches, while Russia faces a larger epidemic burden and higher need for expanded prevention-linked diagnostics and treatment monitoring. China and India represent major volume settings due to population scale, government-led testing programs, blood screening, and expanding molecular infrastructure. Japan, Australia, and South Korea offer advanced laboratory infrastructure, high regulatory standards, and growing interest in rapid, discreet, digitally connected, and patient-centered HIV testing models.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize assay accuracy, fast turnaround time, affordability, and access across clinical, community, and self-testing settings. Portfolio strategies should combine high-throughput laboratory systems, rapid tests, molecular confirmation, early infant diagnosis, viral load monitoring, CD4 testing where clinically relevant, and digital reporting tools to support diagnosis, treatment initiation, and long-term care.

Manufacturers and service providers should strengthen evidence generation, regulatory readiness, quality management, and supply continuity. Strategic partnerships with public health agencies, community organizations, procurement bodies, and reference laboratories can improve reach among high-risk and underserved populations. AI investments should focus on validated use cases such as demand planning, quality control, laboratory workflow optimization, and linkage-to-care analytics rather than replacing established diagnostic algorithms.

Research Methodology for HIV Diagnostics Analysis

This executive summary is grounded in triangulated secondary research from authoritative public health and regulatory sources, including UNAIDS, WHO, CDC, ECDC, FDA, national HIV guidelines, peer-reviewed literature, and official health ministry publications. Market interpretation is aligned with verified epidemiological indicators, testing guidance, diagnostic technology adoption, and regulatory developments.

The methodology emphasizes data validation through cross-source comparison, assessment of regional disease burden, evaluation of testing infrastructure, and review of product categories including immunoassays, rapid tests, nucleic acid testing, CD4 testing, early infant diagnosis, and viral load monitoring. Insights are presented to support strategic planning without relying on unsupported projections, market sizing, market share estimates, or unverified claims.

Conclusion: Diagnostics as the Foundation of HIV Control

HIV and AIDS diagnostics are evolving from traditional clinic-based testing toward integrated, accessible, and data-enabled systems that support prevention, treatment, and surveillance. The sector remains driven by the global need to identify undiagnosed infections, reduce late diagnosis, monitor treatment effectiveness, improve viral suppression, and close gaps across the HIV care continuum.

Organizations that combine clinically validated assays, decentralized access, regulatory discipline, supply reliability, and responsible digital innovation will be best positioned to serve health systems and patients. As countries continue pursuing HIV epidemic control, diagnostics will remain a foundational pillar of public health strategy and sustainable industry growth.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. New Revenue Opportunities
3.5. Next-Generation Business Models
3.6. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. HIV or AIDS Diagnostics Market, by Test Type
7.1. Introduction
7.2. Antibody Tests
7.2.1. ELISA/EIA
7.2.2. Rapid Tests
7.2.3. Western Blot Test
7.3. CD4 Tests
7.4. Viral Load Tests
8. HIV or AIDS Diagnostics Market, by Type of Product
8.1. Introduction
8.2. Consumables & Reagents
8.3. Instruments & Kits
8.4. Software
8.5. Testing Services
9. HIV or AIDS Diagnostics Market, by Testing Method
9.1. Introduction
9.2. Laboratory-Based Testing
9.3. Point-Of-Care Testing
9.4. Self-Testing
10. HIV or AIDS Diagnostics Market, by End-User
10.1. Introduction
10.2. Blood Banks & Transfusion Centers
10.3. Diagnostic Centers
10.4. Home Care Settings
10.5. Hospitals & Clinics
10.6. Research Institutes
11. HIV or AIDS Diagnostics Market, by Application
11.1. Introduction
11.2. Disease Progression
11.3. Monitoring
11.4. Screening
12. HIV or AIDS Diagnostics Market, by Region
12.1. Asia-Pacific
12.2. North America
12.3. Latin America
12.4. Europe
12.5. Middle East
12.6. Africa
13. HIV or AIDS Diagnostics Market, by Group
13.1. ASEAN
13.2. GCC
13.3. European Union
13.4. BRICS
13.5. G7
13.6. NATO
14. HIV or AIDS Diagnostics Market, by Country
14.1. United States
14.2. Germany
14.3. China
14.4. United Kingdom
14.5. India
14.6. Japan
14.7. Russia
14.8. Brazil
14.9. Canada
14.10. Italy
14.11. Mexico
14.12. France
14.13. Spain
14.14. Australia
14.15. South Korea
15. Competitive Landscape
15.1. Market Share Analysis, 2025
15.2. FPNV Positioning Matrix, 2025
15.3. Market Concentration Analysis, 2025
15.3.1. Concentration Ratio (CR)
15.3.2. Herfindahl Hirschman Index (HHI)
15.4. Recent Developments & Impact Analysis, 2025
15.5. Product Portfolio Analysis, 2025
15.6. Benchmarking Analysis, 2025
16. Company Profiles
16.1. Abbott Laboratories
16.2. ACON Laboratories
16.3. Beckman Coulter, Inc.
16.4. Becton, Dickinson and Company
16.5. Bio-Rad Laboratories
16.6. bioMérieux SA
16.7. Chembio Diagnostics, Inc.
16.8. Danaher Corporation
16.9. DiaSorin S.p.A.
16.10. ELITechGroup
16.11. Euroimmun Medizinische Labordiagnostika AG
16.12. F. Hoffmann-La Roche Ltd.
16.13. Hologic, Inc.
16.14. InBios International, Inc.
16.15. OraSure Technologies
16.16. Ortho Clinical Diagnostics, Inc.
16.17. SD Biosensor Inc.
16.18. Siemens Healthineers AG
16.19. Thermo Fisher Scientific, Inc.
16.20. Trinity Biotech plc
16.21. Viracor Eurofins Diagnostic Services
16.22. Wondfo Biotech Co. Ltd.
List of Figures
FIGURE 1. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, 2024-2032 (USD MILLION)
FIGURE 6. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2025 VS 2032 (%)
FIGURE 7. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TYPE OF PRODUCT, 2025 VS 2032 (%)
FIGURE 9. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TYPE OF PRODUCT, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TESTING METHOD, 2025 VS 2032 (%)
FIGURE 11. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TESTING METHOD, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY END-USER, 2025 VS 2032 (%)
FIGURE 13. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY END-USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025 VS 2032 (%)
FIGURE 15. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 17. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 19. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 21. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 23. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
List of Tables
TABLE 1. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 3. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 4. GLOBAL ANTIBODY TESTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 5. GLOBAL ANTIBODY TESTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 6. GLOBAL ANTIBODY TESTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 7. GLOBAL ELISA/EIA MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 8. GLOBAL ELISA/EIA MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 9. GLOBAL ELISA/EIA MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 10. GLOBAL RAPID TESTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 11. GLOBAL RAPID TESTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 12. GLOBAL RAPID TESTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 13. GLOBAL WESTERN BLOT TEST MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 14. GLOBAL WESTERN BLOT TEST MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 15. GLOBAL WESTERN BLOT TEST MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 16. GLOBAL CD4 TESTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 17. GLOBAL CD4 TESTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 18. GLOBAL CD4 TESTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 19. GLOBAL VIRAL LOAD TESTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 20. GLOBAL VIRAL LOAD TESTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 21. GLOBAL VIRAL LOAD TESTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 22. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TYPE OF PRODUCT, 2017-2032 (USD MILLION)
TABLE 23. GLOBAL CONSUMABLES & REAGENTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 24. GLOBAL CONSUMABLES & REAGENTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 25. GLOBAL CONSUMABLES & REAGENTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 26. GLOBAL INSTRUMENTS & KITS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 27. GLOBAL INSTRUMENTS & KITS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 28. GLOBAL INSTRUMENTS & KITS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 29. GLOBAL SOFTWARE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 30. GLOBAL SOFTWARE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 31. GLOBAL SOFTWARE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 32. GLOBAL TESTING SERVICES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 33. GLOBAL TESTING SERVICES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 34. GLOBAL TESTING SERVICES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 35. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TESTING METHOD, 2017-2032 (USD MILLION)
TABLE 36. GLOBAL LABORATORY-BASED TESTING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 37. GLOBAL LABORATORY-BASED TESTING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 38. GLOBAL LABORATORY-BASED TESTING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 39. GLOBAL POINT-OF-CARE TESTING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 40. GLOBAL POINT-OF-CARE TESTING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 41. GLOBAL POINT-OF-CARE TESTING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 42. GLOBAL SELF-TESTING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 43. GLOBAL SELF-TESTING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 44. GLOBAL SELF-TESTING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 45. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 46. GLOBAL BLOOD BANKS & TRANSFUSION CENTERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 47. GLOBAL BLOOD BANKS & TRANSFUSION CENTERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 48. GLOBAL BLOOD BANKS & TRANSFUSION CENTERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 49. GLOBAL DIAGNOSTIC CENTERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 50. GLOBAL DIAGNOSTIC CENTERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 51. GLOBAL DIAGNOSTIC CENTERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 52. GLOBAL HOME CARE SETTINGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 53. GLOBAL HOME CARE SETTINGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 54. GLOBAL HOME CARE SETTINGS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 55. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 56. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 57. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 58. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 59. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 60. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 61. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 62. GLOBAL DISEASE PROGRESSION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 63. GLOBAL DISEASE PROGRESSION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 64. GLOBAL DISEASE PROGRESSION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 65. GLOBAL MONITORING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 66. GLOBAL MONITORING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 67. GLOBAL MONITORING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 68. GLOBAL SCREENING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 69. GLOBAL SCREENING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 70. GLOBAL SCREENING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 71. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 72. ASIA-PACIFIC HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 73. ASIA-PACIFIC HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 74. ASIA-PACIFIC HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY ANTIBODY TESTS, 2017-2032 (USD MILLION)
TABLE 75. ASIA-PACIFIC HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TYPE OF PRODUCT, 2017-2032 (USD MILLION)
TABLE 76. ASIA-PACIFIC HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TESTING METHOD, 2017-2032 (USD MILLION)
TABLE 77. ASIA-PACIFIC HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 78. ASIA-PACIFIC HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 79. NORTH AMERICA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 80. NORTH AMERICA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 81. NORTH AMERICA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY ANTIBODY TESTS, 2017-2032 (USD MILLION)
TABLE 82. NORTH AMERICA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TYPE OF PRODUCT, 2017-2032 (USD MILLION)
TABLE 83. NORTH AMERICA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TESTING METHOD, 2017-2032 (USD MILLION)
TABLE 84. NORTH AMERICA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 85. NORTH AMERICA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 86. LATIN AMERICA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 87. LATIN AMERICA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 88. LATIN AMERICA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY ANTIBODY TESTS, 2017-2032 (USD MILLION)
TABLE 89. LATIN AMERICA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TYPE OF PRODUCT, 2017-2032 (USD MILLION)
TABLE 90. LATIN AMERICA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TESTING METHOD, 2017-2032 (USD MILLION)
TABLE 91. LATIN AMERICA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 92. LATIN AMERICA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 93. EUROPE HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 94. EUROPE HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 95. EUROPE HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY ANTIBODY TESTS, 2017-2032 (USD MILLION)
TABLE 96. EUROPE HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TYPE OF PRODUCT, 2017-2032 (USD MILLION)
TABLE 97. EUROPE HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TESTING METHOD, 2017-2032 (USD MILLION)
TABLE 98. EUROPE HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 99. EUROPE HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 100. MIDDLE EAST HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 101. MIDDLE EAST HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 102. MIDDLE EAST HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY ANTIBODY TESTS, 2017-2032 (USD MILLION)
TABLE 103. MIDDLE EAST HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TYPE OF PRODUCT, 2017-2032 (USD MILLION)
TABLE 104. MIDDLE EAST HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TESTING METHOD, 2017-2032 (USD MILLION)
TABLE 105. MIDDLE EAST HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 106. MIDDLE EAST HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 107. AFRICA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 108. AFRICA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 109. AFRICA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY ANTIBODY TESTS, 2017-2032 (USD MILLION)
TABLE 110. AFRICA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TYPE OF PRODUCT, 2017-2032 (USD MILLION)
TABLE 111. AFRICA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TESTING METHOD, 2017-2032 (USD MILLION)
TABLE 112. AFRICA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 113. AFRICA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 114. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 115. ASEAN HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 116. ASEAN HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 117. ASEAN HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY ANTIBODY TESTS, 2017-2032 (USD MILLION)
TABLE 118. ASEAN HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TYPE OF PRODUCT, 2017-2032 (USD MILLION)
TABLE 119. ASEAN HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TESTING METHOD, 2017-2032 (USD MILLION)
TABLE 120. ASEAN HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 121. ASEAN HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 122. GCC HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 123. GCC HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 124. GCC HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY ANTIBODY TESTS, 2017-2032 (USD MILLION)
TABLE 125. GCC HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TYPE OF PRODUCT, 2017-2032 (USD MILLION)
TABLE 126. GCC HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TESTING METHOD, 2017-2032 (USD MILLION)
TABLE 127. GCC HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 128. GCC HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 129. EUROPEAN UNION HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 130. EUROPEAN UNION HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 131. EUROPEAN UNION HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY ANTIBODY TESTS, 2017-2032 (USD MILLION)
TABLE 132. EUROPEAN UNION HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TYPE OF PRODUCT, 2017-2032 (USD MILLION)
TABLE 133. EUROPEAN UNION HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TESTING METHOD, 2017-2032 (USD MILLION)
TABLE 134. EUROPEAN UNION HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 135. EUROPEAN UNION HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 136. BRICS HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 137. BRICS HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 138. BRICS HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY ANTIBODY TESTS, 2017-2032 (USD MILLION)
TABLE 139. BRICS HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TYPE OF PRODUCT, 2017-2032 (USD MILLION)
TABLE 140. BRICS HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TESTING METHOD, 2017-2032 (USD MILLION)
TABLE 141. BRICS HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 142. BRICS HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 143. G7 HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 144. G7 HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 145. G7 HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY ANTIBODY TESTS, 2017-2032 (USD MILLION)
TABLE 146. G7 HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TYPE OF PRODUCT, 2017-2032 (USD MILLION)
TABLE 147. G7 HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TESTING METHOD, 2017-2032 (USD MILLION)
TABLE 148. G7 HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 149. G7 HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 150. NATO HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 151. NATO HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 152. NATO HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY ANTIBODY TESTS, 2017-2032 (USD MILLION)
TABLE 153. NATO HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TYPE OF PRODUCT, 2017-2032 (USD MILLION)
TABLE 154. NATO HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TESTING METHOD, 2017-2032 (USD MILLION)
TABLE 155. NATO HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 156. NATO HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 157. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 158. UNITED STATES HIV OR AIDS DIAGNOSTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 159. UNITED STATES HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 160. UNITED STATES HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY ANTIBODY TESTS, 2017-2032 (USD MILLION)
TABLE 161. UNITED STATES HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TYPE OF PRODUCT, 2017-2032 (USD MILLION)
TABLE 162. UNITED STATES HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TESTING METHOD, 2017-2032 (USD MILLION)
TABLE 163. UNITED STATES HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 164. UNITED STATES HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 165. GERMANY HIV OR AIDS DIAGNOSTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 166. GERMANY HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 167. GERMANY HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY ANTIBODY TESTS, 2017-2032 (USD MILLION)
TABLE 168. GERMANY HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TYPE OF PRODUCT, 2017-2032 (USD MILLION)
TABLE 169. GERMANY HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TESTING METHOD, 2017-2032 (USD MILLION)
TABLE 170. GERMANY HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 171. GERMANY HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 172. CHINA HIV OR AIDS DIAGNOSTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 173. CHINA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 174. CHINA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY ANTIBODY TESTS, 2017-2032 (USD MILLION)
TABLE 175. CHINA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TYPE OF PRODUCT, 2017-2032 (USD MILLION)
TABLE 176. CHINA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TESTING METHOD, 2017-2032 (USD MILLION)
TABLE 177. CHINA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 178. CHINA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 179. UNITED KINGDOM HIV OR AIDS DIAGNOSTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 180. UNITED KINGDOM HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 181. UNITED KINGDOM HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY ANTIBODY TESTS, 2017-2032 (USD MILLION)
TABLE 182. UNITED KINGDOM HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TYPE OF PRODUCT, 2017-2032 (USD MILLION)
TABLE 183. UNITED KINGDOM HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TESTING METHOD, 2017-2032 (USD MILLION)
TABLE 184. UNITED KINGDOM HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 185. UNITED KINGDOM HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 186. INDIA HIV OR AIDS DIAGNOSTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 187. INDIA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 188. INDIA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY ANTIBODY TESTS, 2017-2032 (USD MILLION)
TABLE 189. INDIA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TYPE OF PRODUCT, 2017-2032 (USD MILLION)
TABLE 190. INDIA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TESTING METHOD, 2017-2032 (USD MILLION)
TABLE 191. INDIA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 192. INDIA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 193. JAPAN HIV OR AIDS DIAGNOSTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 194. JAPAN HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 195. JAPAN HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY ANTIBODY TESTS, 2017-2032 (USD MILLION)
TABLE 196. JAPAN HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TYPE OF PRODUCT, 2017-2032 (USD MILLION)
TABLE 197. JAPAN HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TESTING METHOD, 2017-2032 (USD MILLION)
TABLE 198. JAPAN HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 199. JAPAN HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 200. RUSSIA HIV OR AIDS DIAGNOSTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 201. RUSSIA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 202. RUSSIA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY ANTIBODY TESTS, 2017-2032 (USD MILLION)
TABLE 203. RUSSIA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TYPE OF PRODUCT, 2017-2032 (USD MILLION)
TABLE 204. RUSSIA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TESTING METHOD, 2017-2032 (USD MILLION)
TABLE 205. RUSSIA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 206. RUSSIA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 207. BRAZIL HIV OR AIDS DIAGNOSTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 208. BRAZIL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 209. BRAZIL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY ANTIBODY TESTS, 2017-2032 (USD MILLION)
TABLE 210. BRAZIL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TYPE OF PRODUCT, 2017-2032 (USD MILLION)
TABLE 211. BRAZIL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TESTING METHOD, 2017-2032 (USD MILLION)
TABLE 212. BRAZIL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 213. BRAZIL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 214. CANADA HIV OR AIDS DIAGNOSTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 215. CANADA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 216. CANADA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY ANTIBODY TESTS, 2017-2032 (USD MILLION)
TABLE 217. CANADA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TYPE OF PRODUCT, 2017-2032 (USD MILLION)
TABLE 218. CANADA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TESTING METHOD, 2017-2032 (USD MILLION)
TABLE 219. CANADA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 220. CANADA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 221. ITALY HIV OR AIDS DIAGNOSTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 222. ITALY HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 223. ITALY HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY ANTIBODY TESTS, 2017-2032 (USD MILLION)
TABLE 224. ITALY HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TYPE OF PRODUCT, 2017-2032 (USD MILLION)
TABLE 225. ITALY HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TESTING METHOD, 2017-2032 (USD MILLION)
TABLE 226. ITALY HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 227. ITALY HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 228. MEXICO HIV OR AIDS DIAGNOSTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 229. MEXICO HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 230. MEXICO HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY ANTIBODY TESTS, 2017-2032 (USD MILLION)
TABLE 231. MEXICO HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TYPE OF PRODUCT, 2017-2032 (USD MILLION)
TABLE 232. MEXICO HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TESTING METHOD, 2017-2032 (USD MILLION)
TABLE 233. MEXICO HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 234. MEXICO HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 235. FRANCE HIV OR AIDS DIAGNOSTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 236. FRANCE HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 237. FRANCE HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY ANTIBODY TESTS, 2017-2032 (USD MILLION)
TABLE 238. FRANCE HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TYPE OF PRODUCT, 2017-2032 (USD MILLION)
TABLE 239. FRANCE HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TESTING METHOD, 2017-2032 (USD MILLION)
TABLE 240. FRANCE HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 241. FRANCE HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 242. SPAIN HIV OR AIDS DIAGNOSTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 243. SPAIN HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 244. SPAIN HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY ANTIBODY TESTS, 2017-2032 (USD MILLION)
TABLE 245. SPAIN HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TYPE OF PRODUCT, 2017-2032 (USD MILLION)
TABLE 246. SPAIN HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TESTING METHOD, 2017-2032 (USD MILLION)
TABLE 247. SPAIN HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 248. SPAIN HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 249. AUSTRALIA HIV OR AIDS DIAGNOSTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 250. AUSTRALIA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 251. AUSTRALIA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY ANTIBODY TESTS, 2017-2032 (USD MILLION)
TABLE 252. AUSTRALIA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TYPE OF PRODUCT, 2017-2032 (USD MILLION)
TABLE 253. AUSTRALIA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TESTING METHOD, 2017-2032 (USD MILLION)
TABLE 254. AUSTRALIA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 255. AUSTRALIA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 256. SOUTH KOREA HIV OR AIDS DIAGNOSTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 257. SOUTH KOREA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 258. SOUTH KOREA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY ANTIBODY TESTS, 2017-2032 (USD MILLION)
TABLE 259. SOUTH KOREA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TYPE OF PRODUCT, 2017-2032 (USD MILLION)
TABLE 260. SOUTH KOREA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TESTING METHOD, 2017-2032 (USD MILLION)
TABLE 261. SOUTH KOREA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 262. SOUTH KOREA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 263. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2025
TABLE 264. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025

Companies Mentioned

  • Abbott Laboratories
  • ACON Laboratories
  • Beckman Coulter, Inc.
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories
  • bioMérieux SA
  • Chembio Diagnostics, Inc.
  • Danaher Corporation
  • DiaSorin S.p.A.
  • ELITechGroup
  • Euroimmun Medizinische Labordiagnostika AG
  • F. Hoffmann-La Roche Ltd.
  • Hologic, Inc.
  • InBios International, Inc.
  • OraSure Technologies
  • Ortho Clinical Diagnostics, Inc.
  • SD Biosensor Inc.
  • Siemens Healthineers AG
  • Thermo Fisher Scientific, Inc.
  • Trinity Biotech plc
  • Viracor Eurofins Diagnostic Services
  • Wondfo Biotech Co. Ltd.

Table Information

Report AttributeDetails
No. of Pages196
PublishedAugust 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 2.76 Billion
Forecasted Market Value ( USD ) by 2032 $ 4.06 Billion
Compound Annual Growth Rate6.5%
Regions CoveredGlobal
No. of Companies Mentioned22

Related Topics

Related Reports

Infectious Disease Diagnostic Market - Global Forecast 2026-2032 - Product Image

Infectious Disease Diagnostic Market - Global Forecast 2026-2032

  • Report
  • 190 Pages
  • Global
From
HIV Self-Test Kit Market - Global Forecast 2026-2032 - Product Image

HIV Self-Test Kit Market - Global Forecast 2026-2032

  • Report
  • 191 Pages
  • Global
From
HIV/AIDS Testing - Global Strategic Business Report - Product Image

HIV/AIDS Testing - Global Strategic Business Report

  • Report
  • 202 Pages
  • Global
From
HIV Drugs Market Size, Share, Trends and Forecast by Drug Class, Distribution Channel, and Region, 2026-2034 - Product Image

HIV Drugs Market Size, Share, Trends and Forecast by Drug Class, Distribution Channel, and Region, 2026-2034

  • Report
  • 138 Pages
  • Global
From
HIV Diagnostics Market Insights, Competitive Landscape, and Market Forecast - 2033 - Product Image

HIV Diagnostics Market Insights, Competitive Landscape, and Market Forecast - 2033

  • Report
  • 200 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.